ClinicalTrials.gg

Program

xelox

Also written as “XELOX”, “IDX-1197+XELOX” and “SSGJ-706+Bevacizumab+XELOX”.

Its studies are mostly in Colorectal Neoplasms · Stomach Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 7 companies.

Furthest: phase 3, since Nov 13, 20068 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca21 open or runningphase 3since Nov 13, 2006Nov 13, 2006Nov 30, 2027phase 2 · NCT05702229
3SBio11 open or runningphase 2since Nov 14, 2025Nov 14, 2025Dec 2026phase 2 · NCT07233850
GlaxoSmithKline10 open or runningphase 1since Oct 11, 2006Oct 11, 2006none ahead
Hansoh Pharmaceutical Group11 open or runningphase 1since Sep 29, 2024Sep 29, 2024none ahead
Hoffmann-La Roche10 open or runningphase 3since Jul 6, 2006Jul 6, 2006none ahead
Idience11 open or runningphase 2since Jan 13, 2021Jan 13, 2021none ahead
Sichuan Luzhou Buchang Biopharmaceutical11 open or runningphase 1since Jan 2, 2025Jan 2, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 6, 2006First study: phase 3 study in Colorectal NeoplasmsNew to Hoffmann-La RocheHoffmann-La Roche · NCT00349336 · 64 enrolled · Australia, Canada, New Zealand
  2. Oct 11, 2006GlaxoSmithKline's first study: phase 1 study in Colorectal NeoplasmsNew to GlaxoSmithKlineGlaxoSmithKline · NCT00387387 · 50 enrolled · India, United Kingdom
  3. Nov 13, 2006AstraZeneca's first study: phase 3 study in Colorectal NeoplasmsNew to AstraZenecaAstraZeneca · NCT00399035 · 1,254 enrolled · Argentina, Australia, Brazil and more
  4. Jan 13, 2021Idience's first study: phase 2 study in Stomach NeoplasmsNew to IdienceIdience · NCT04725994 · 87 enrolled · United States, China, South Korea
  5. Dec 7, 2022Phase 2 study in Stomach NeoplasmsAstraZeneca · NCT05702229 · 163 planned · United States, China, Japan and more
  6. Sep 29, 2024Hansoh Pharmaceutical Group's first study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT06621563 · 780 planned · China
  7. Jan 2, 2025Sichuan Luzhou Buchang Biopharmaceutical's first study: phase 1 study in Stomach NeoplasmsNew to Sichuan Luzhou Buchang BiopharmaceuticalSichuan Luzhou Buchang Biopharmaceutical · NCT06773312 · 80 planned · China
  8. Nov 14, 20253SBio's first study: phase 2 study in Colorectal NeoplasmsNew to 3SBio3SBio · NCT07233850 · 300 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Colorectal Neoplasms3SBio · NCT07233850
  2. Nov 30, 2027Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT05702229

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07233850Colorectal Neoplasms · China2Not yet recruiting3SBioDec 2026300
NCT06773312Stomach Neoplasms · China1RecruitingSichuan Luzhou Buchang BiopharmaceuticalOct 202680
NCT06621563Carcinoma, Non-Small-Cell Lung · China1RecruitingHansoh Pharmaceutical GroupMar 30, 2026780
NCT05702229Stomach Neoplasms · United States, China, Japan and more2RecruitingAstraZenecaNov 30, 2027163
NCT04725994Stomach Neoplasms · United States, China, South Korea2Active, not recruitingIdienceJul 31, 202687
NCT00399035Colorectal Neoplasms · Argentina, Australia, Brazil and more3CompletedAstraZenecaMar 20101,254
NCT00387387Colorectal Neoplasms · India, United Kingdom1CompletedGlaxoSmithKlineAug 14, 200950
NCT00349336Colorectal Neoplasms · Australia, Canada, New Zealand3CompletedHoffmann-La RocheNov 200864

How it is read

Names in the registry

  • “XELOX”, 2 entries
  • “IDX-1197+XELOX”, 1 entry
  • “SSGJ-706+Bevacizumab+XELOX”, 1 entry
  • “HS-20117+CAPEOX”, 1 entry
  • “BC001+Sintilimab+XELOX”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.